First results of the COVID-19 in ms global data sharing initiative suggest anti-CD20 dmts are associated with worse covid-19 outcomes

Liesbet M. Peeters(Hasselt University), Melinda Magyari(University of Copenhagen), Tim Spelman(Peter Doherty Institute), Lotte Geys(Hasselt University), Edward De Brouwer(KU Leuven), Richard Nicholas(Swansea University), Nick Rijke(Multiple Sclerosis International Federation), Amber Salter(Salter School), Tomáš Kalinčík(The Royal Melbourne Hospital), Carolina Walton, A. Bergmann, Yves Moreau(Dynamic Systems (United States)), Anneke van der Walt(The Alfred Hospital), Amaya Zabalza(Spanish Multiple Sclerosis Network), Gıancarlo Comı(Vita-Salute San Raffaele University), Alexander Stahmann(Unknown), R Ivanov, Amin Ardeshirdavani(KU Leuven), María Fernanda Mendes(Irmandade da Santa Casa de Misericórdia de São Paulo), Aníbal Chertcoff(Hospital Británico de Buenos Aires), Robert McBurney(Accelerated Cure Project for Multiple Sclerosis), Nikola Lazovski, Jan Hillert, Ashkan Pirmani(Hasselt University), Ingrid van der Mei(University of Tasmania), Tina Parciak(Universitätsmedizin Göttingen), Doralina Guimarães Brum(National Cancer Center), Georgina Arrambide(Universitat Autònoma de Barcelona), Clément Gautrais(KU Leuven), R. Alonso, Gilles Edan(Centre National de la Recherche Scientifique), Guilherme Sciascia do Olival(Brazilian Medical Association), Angélica F. S. Dias, Stefan Braune, Lars Forsberg, Anna Glaser(Karolinska Institutet), Jhojan P. Rojas, Johann Bauer, Rod Middleton(Swansea University), H. R. Schmidt

HAL (Le Centre pour la Communication Scientifique Directe)

January 1, 2020

Cited by 6

|Annals of Neurology|2001|7k

|Annals of Neurology|2005|5k

|Multiple Sclerosis Journal|2020|2.5k

|New England Journal of Medicine|2010|2.2k

|New England Journal of Medicine|2016|2k

Related Papers